168 results on '"Iori, Anna P."'
Search Results
2. Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial
3. Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic
4. Multi-parametric MRI in the diagnosis and scoring of gastrointestinal acute graft-versus-host disease
5. Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01
6. Donor specific anti-HLA antibodies in hematopoietic stem cell transplantation. Single center prospective evaluation and desensitization strategies employed.
7. Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study
8. Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT
9. Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience
10. Reduced mortality from KPC-K.pneumoniae bloodstream infection in high-risk patients with hematological malignancies colonized by KPC-K.pneumoniae
11. Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients
12. Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs
13. Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol
14. Risk factors associated with development and mortality by invasive fungal diseases in pediatric allogeneic stem cell transplantation. A pediatric subgroup analysis of data from a prospective study of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
15. Correction to: Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience
16. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial
17. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
18. Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
19. Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience
20. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection
21. COVID‐19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey
22. Concurrent search for unrelated cord and volunteer donor in high-risk acute lymphoblastic leukemia
23. Functional analysis and gene expression profile of umbilical cord blood regulatory T cells
24. From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging
25. Clinical responses in allografted acute leukaemia patients with resistant disease using a combined chemo-immunotherapeutic treatment strategy
26. GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms
27. Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study
28. Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia
29. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
30. Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab
31. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
32. The Functional Capacities of Peripheral Blood Regulatory T Cells after an Allogeneic Stem Cell Transplant Correlate with the Risk of Graft-Versus-Host Disease
33. Antiphospholipid Antibodies and Thrombotic Complications In Patients With Paroxysmal Nocturnal Hemoglobinuria
34. The immune reconstitution after an allogeneic stem cell transplant correlates with the risk of graft-versus-host disease and cytomegalovirus infection
35. Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs.
36. Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
37. An update on the safety and interactions of antifungal drugs in stem cell transplant recipients
38. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study
39. Early onset of posterior reversible encephalopathy syndrome (PRES) during Cyclosporine-A infusion
40. Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation
41. B-Cell Concentration in the Apheretic Product Predicts Acute Graft-Versus-Host Disease and Treatment-Related Mortality of Allogeneic Peripheral Blood Stem Cell Transplantation
42. T Regulatory Cells Obtained from Cord Blood Are Greatly Expandable and Exert Potent Suppressive Function.
43. WHO Classification and WPSS Score Predict Post-Transplant Outcome in Adults with Myelodysplastic Syndrome: A Retrospective Study by GITMO - Gruppo Italiano Trapianto Midollo Osseo.
44. Favourable Outcome after Treosulfan Based Conditioning in Patients Undergoing an Allogeneic Hematopoietic Cell Transplantation (alloHCT) for the Treatment of Acute Myleloid Leukaemia (AML): A Subgroup Analysis of the Randomized Phase III MC-Fludt.14/L Trial
45. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R
46. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy
47. COVID-19 Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy
48. Safety and interactions of new antifungals in stem cell transplant recipients
49. No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission
50. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.